Inventiva (IVA) Invested Capital (2018 - 2025)
Inventiva (IVA) posted quarterly Invested Capital of $302.2 million for Q4 2025, up 31.89% year-over-year from $229.2 million in Q4 2024, and up 55.13% quarter-over-quarter from $194.8 million in Q2 2025.
Analysis
Inventiva (IVA) Invested Capital (2018 - 2025) Analysis & Trends
Inventiva's Invested Capital history runs 8 years deep, the most recent figure standing at $302.2 million for Q4 2025.
- In Q4 2025, Invested Capital rose 31.89% year-over-year to $302.2 million; the TTM figure through Dec 2025 stood at $844.7 million (up 89.23% YoY), while the FY2025 annual figure was $302.2 million, up 31.89% from the prior year.
- Invested Capital for Q4 2025 stood at $302.2 million, up from $194.8 million in the prior quarter.
- The five-year high for Invested Capital was $302.2 million in Q4 2025, with the low at $31.7 million in Q4 2021.
- The 5-year median for Invested Capital is $108.6 million (2023), against an average of $139.8 million.
- The sharpest annual moves came in 2021 and 2024: Invested Capital soared 31.73% in 2021, then soared 132.04% in 2024.
- Inventiva's Invested Capital stood at $31.7 million in 2021, then soared by 105.28% to $65.1 million in 2022, then soared by 51.81% to $98.8 million in 2023, then jumped by 132.04% to $229.2 million in 2024, then soared by 31.89% to $302.2 million in 2025.
- Business Quant data shows IVA's Invested Capital at $302.2 million in Q4 2025, $194.8 million in Q2 2025, and $229.2 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 33.70 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 7.35 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 6.25 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.13 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.30 Bn |
| 10 | Inventiva | 893.85 Mn | 893.85 Mn | - | -33.13 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -33.13 Bn |
| Jun 30, 2025 | 102.41 Mn |
| Dec 31, 2024 | 48.51 Mn |
| Jun 30, 2024 | -13.91 Mn |
| Dec 31, 2023 | 20.47 Mn |
| Jun 30, 2023 | 38.90 Mn |
| Dec 31, 2022 | 91.69 Mn |
| Jun 30, 2022 | 94.18 Mn |
| Dec 31, 2021 | 113.24 Mn |
| Jun 30, 2021 | 118.76 Mn |
| Mar 31, 2021 | 135.51 Mn |
| Dec 31, 2020 | 144.58 Mn |
| Jun 30, 2020 | 57.01 Mn |
| Dec 31, 2019 | 45.94 Mn |
| Dec 31, 2018 | 70.73 Mn |